ABL Bio Inc.

A298380

KR7298380007

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
26,400 ^KRW	+6.45%		+14.53%	+7.32%

Mar. 25	Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	CI
2023	ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index

June 24, 2019 at 12:00 am EDT

Latest news about ABL Bio Inc.

Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	Mar. 25	CI
ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
I-Mab Doses First Patient in Phase 1 Trial of TJ-CD4B to Treat Solid Tumors	22-07-22	MT
ABL Bio Inc. Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease	22-01-11	CI
I-Mab and ABL Bio Inc. Jointly Announce Preclinical Data of Their 4-1Bb Bispecific Antibodies At the 2021 Society for Immunotherapy of Cancer Annual Meeting	21-11-12	CI
Compass Therapeutics, Inc. and ABL Bio Presented Clinical Trial Data for CTX-009	21-10-08	CI
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting	21-10-05	CI
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody	21-08-04	CI
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody	21-07-09	CI
I-Mab and ABL Bio Inc. Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors	21-04-06	CI
I-Mab and ABL Bio Inc. Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors	21-03-30	CI
HiFiBiO Therapeutics Announces Global Strategic Partnership with ABL Bio for the Co-Development of SARS-CoV-2 Neutralizing Antibody	20-09-14	CI
I-Mab and ABL Bio Inc. to Present Preclinical Data for Joint Bispecific	20-06-15	CI
Genscript Biologics Enters into an Agreement with ABL Bio Inc	19-11-18	CI
ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index	19-06-24	CI
ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index	19-06-24	CI
ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index	19-06-24	CI
ABL Bio Inc. has completed an IPO in the amount of KRW 90 billion.	18-12-14	CI
TRIGR Therapeutics, Inc. and ABL Bio, Inc. Enters into Collaboration and License Agreement for TR009	18-12-03	CI
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies	18-11-28	CI
ABL Bio Inc. has filed an IPO.	18-09-06	CI

ABL Bio Inc. is a company mainly engaged in the development of biopharmaceuticals. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABL BIO INC.	+7.32%	919M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.95%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.68%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs

ABL Bio Inc.

Equities

A298380

KR7298380007

Biotechnology & Medical Research

ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index

Latest news about ABL Bio Inc.

Chart ABL Bio Inc.

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs